Beyond the Irregular Beat: An Unexpected Case of Raynaud’s Phenomenon in a Patient with Atrial Fibrillation

Authors

  • Ni Putu Widyanti Suastiari Faculty of Medicine, Wijaya Kusuma Surabaya University, Surabaya, Indonesia
  • Rahmania Rahmania 1. Department of Internal Medicine, Faculty of Medicine, Wijaya Kusuma Surabaya University - Dr. Mohamad Saleh General Hospital, Probolinggo, East Java, Indonesia. 2. Division of Cardiology and Vascular Medicine, Department of Internal Medicine, Faculty of Medicine, Wijaya Kusuma Surabaya University - Dr. Mohamad Saleh General Hospital, Probolinggo, East Java, Indonesia.
  • Riawati Utama Faculty of Medicine, Wijaya Kusuma Surabaya University, Surabaya, Indonesia

Keywords:

Raynaud's Phenomenon, Atrial Fibrillation, Pulmonary Arterial Hypertension, Systemic Sclerosis

Abstract

Raynaud's phenomenon is characterized by episodic vasospasm of the extremities, often triggered by cold or stress. It is a hallmark of systemic sclerosis (SSc) and is frequently associated with pulmonary arterial hypertension (PAH). PAH may cause right atrial dilatation, predisposing to atrial fibrillation (AF). While Raynaud’s and PAH are well-documented, their coexistence with AF is rarely reported. A 71-year-old male presented with rapid AF and pulmonary oedema. On admission, vital signs were stable, but he developed symmetrical discoloration of the fingers, palms, and feet after cold exposure in the ICU, accompanied by numbness and pain. Laboratory tests revealed prolonged PT, high ESR (65/121 mm/hr), and positive ANA (44.8 IU/mL). ECG showed rapid AF with left ventricular hypertrophy. Chest X-ray demonstrated pulmonary artery dilatation and cardiomegaly. Echocardiography revealed moderate tricuspid regurgitation and severe PAH. This case illustrates a rare combination of Raynaud’s phenomenon, PAH, and AF, likely secondary to autoimmune vascular dysfunction. PAH-induced atrial dilatation may trigger AF, while endothelial dysfunction may worsen Raynaud’s symptoms. A positive ANA suggests underlying SSc or SLE. Early recognition and multidisciplinary management targeting pulmonary pressure, arrhythmia control, and vasospasm are crucial to prevent complications. Long-term outcome was not assessed due to loss to follow-up.

References

Curtiss P, Svigos K, Schwager Z, Lo Sicco K, Franks AG. Part I: Epidemiology, pathophysiology, and clinical considerations of primary and secondary Raynaud’s phenomenon. J Am Acad Dermatol. 2024 Feb;90(2):223–34.

Wigley FM, Flavahan NA. Raynaud’s phenomenon. New England Journal of Medicine. 2016 Aug 11;375(6):556–65.

Maciejewska M, Sikora M, Maciejewski C, Alda-Malicka R, Czuwara J, Rudnicka L. Raynaud’s phenomenon with focus on systemic sclerosis. J Clin Med. 2022 Apr 28;11(9):2490.

Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618–731.

Anand S, Cronin EM. Arrhythmias in patients with pulmonary hypertension and right ventricular failure: Importance of rhythm control strategies. J Clin Med. 2024 Mar 24;13(7):1866.

Patnaik E, Lyons M, Tran K, Pattanaik D. Endothelial dysfunction in systemic sclerosis. Int J Mol Sci. 2023 Sep 21;24(18):14385.

Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines – the diagnosis and management of Raynaud’s phenomenon. Vasa. 2017 Oct 1;46(6):413–23.

Downloads

Published

2026-07-03

How to Cite

Suastiari, N. P. W. ., Rahmania, R., & Utama, R. . (2026). Beyond the Irregular Beat: An Unexpected Case of Raynaud’s Phenomenon in a Patient with Atrial Fibrillation. Acta Medica Indonesiana, 58(2), 277. Retrieved from https://actamedindones.org/index.php/ijim/article/view/3079